Ambrx tries another IPO as it chases down HER2 rivalsCalifornia biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Share XAmbrx tries another IPO as it chases down HER2 rivalshttps://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/
Arecor heads for London Stock Exchange with drug reformulation strategyArecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its Share XArecor heads for London Stock Exchange with drug reformulation strategyhttps://pharmaphorum.com/views-and-analysis/arecor-heads-for-london-stock-exchange-with-drug-reformulation-strategy/
Centessa plans $100m IPO to fund R&D and potential acquisitionsCentessa has announced plans for a $100m US IPO just weeks after the company launched with $250m in Share XCentessa plans $100m IPO to fund R&D and potential acquisitionshttps://pharmaphorum.com/news/centessa-plans-100m-ipo-to-fund-rd-and-potential-acquisitions/
Cancer Research UK spinout Achilles raises $175.5m in IPOUK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that Share XCancer Research UK spinout Achilles raises $175.5m in IPOhttps://pharmaphorum.com/news/cancer-research-uk-spinout-achilles-raises-175-5m-in-ipo/
Protein misfolding specialist Gain nets $40m from IPOGain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery Share XProtein misfolding specialist Gain nets $40m from IPOhttps://pharmaphorum.com/news/protein-misfolding-specialist-gain-nets-40m-from-ipo/
Rubius launches $200m IPO to fund red blood cell therapiesRubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel Share XRubius launches $200m IPO to fund red blood cell therapieshttps://pharmaphorum.com/news/rubius-launches-200m-ipo-for-red-blood-cell-therapies/
UK biotech investment at record levels amid COVID-19New figures have confirmed that the UK’s biotech sector received a massive boost from the COVID-19 pandemic last Share XUK biotech investment at record levels amid COVID-19https://pharmaphorum.com/news/uk-biotech-investment-at-record-levels-amid-covid-19/
AI drug discovery biotech AbCellera eyes record IPOAbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and Share XAI drug discovery biotech AbCellera eyes record IPOhttps://pharmaphorum.com/news/ai-drug-discovery-biotech-abcellera-eyes-record-ipo/
UK biotech sector sets new record with more than £1bn investment in Q3There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, Share XUK biotech sector sets new record with more than £1bn investment in Q3https://pharmaphorum.com/news/uk-biotech-sector-sets-new-record-with-more-than-1bn-investment-in-q3/
